Your Health, We Care
Release date: 2026-01-28 17:54:51 Article From: Lucius Laos Recommended: 7
Rivimeinib is available in three tablet strengths: 25 mg, 110 mg, and 160 mg.
The most common side effects of Revuforj include bleeding, nausea and vomiting, muscle or joint pain, infections, abnormal liver function test results, febrile neutropenia, diarrhea or constipation, differentiation syndrome, cardiac rhythm changes, loss of appetite, fluid retention, and fatigue. If you experience any of these side effects that bother you, inform your healthcare provider. In addition, Revuforj may cause other unlisted side effects; if you suspect you have developed any drug-related side effects, contact your healthcare provider promptly.
Recommended Dosage of Rivimeinib (Revuforj) for Acute Leukemia or Acute Myeloid Leukemia (AML)
Without concomitant strong CYP3A4 inhibitors: 270 mg orally, twice daily
With concomitant strong CYP3A4 inhibitors: 160 mg orally, twice daily
Dosage is calculated based on body surface area (BSA), and the administered dose can be determined with reference to the table below:
Without concomitant strong CYP3A4 inhibitors: 160 mg/m² orally, twice daily
With concomitant strong CYP3A4 inhibitors: 95 mg/m² orally, twice daily
For the specific administered dose corresponding to the body surface area, please refer to the official prescribing information for Rivimeinib (Revuforj).
Active ingredient: Rivimeinib
Inactive ingredients: Microcrystalline cellulose, calcium hydrogen phosphate, crospovidone, hypromellose, sodium bicarbonate, colloidal silicon dioxide (hydrophobic), magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide.
The 110 mg strength tablets additionally contain yellow iron oxide.
The 160 mg strength tablets additionally contain FD&C Blue No.2/Indigo Carmine Aluminum Lake (approved by the drug regulatory authority).
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：732025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3692024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：652025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：822025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：822025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：942025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：952025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
